T1	Concept 37 46	monocytes
T2	Concept 51 62	macrophages
T3	Action 67 74	produce
T4	Concept 92 100	cytokine
T5	Concept 75 91	pro-inflammatory
R1	subject Arg1:T3 Arg2:T2	
R2	subject Arg1:T3 Arg2:T1	
R3	has-property Arg1:T4 Arg2:T5	
R5	target Arg1:T3 Arg2:T4	
T6	Concept 115 149	hepatitis virus strain-3 infection
R4	in-time Arg1:T3 Arg2:T6	
T7	Concept 108 114	murine
R6	has-property Arg1:T6 Arg2:T7	
T8	Concept 163 173	SARS-CoV-2
T9	Action 179 187	triggers
T10	Action 197 204	release
T11	Concept 188 196	cytokine
R7	target Arg1:T10 Arg2:T11	
R8	subject Arg1:T9 Arg2:T8	
R9	target Arg1:T9 Arg2:T10	
T12	Concept 210 219	monocytes
R10	subject Arg1:T10 Arg2:T12	
T13	Concept 224 235	macrophages
R11	subject Arg1:T10 Arg2:T13	
T14	Concept 239 256	COVID-19 patients
R12	target Arg1:T10 Arg2:T14	
T15	Concept 430 437	RT-LAMP
T16	Concept 438 444	assays
R13	has-property Arg1:T16 Arg2:T15	
T17	Concept 458 464	usable
R14	has-property Arg1:T16 Arg2:T17	
T18	Concept 469 484	screening tests
R15	target Arg1:T17 Arg2:T18	
T19	Action 342 353	considering
T20	Action 420 429	suggested
R16	causes Arg1:T19 Arg2:T20	
T21	Concept 365 369	load
R17	target Arg1:T19 Arg2:T21	
T22	Concept 359 364	viral
A1	Emphasized T22
T23	Concept 373 383	SARS-CoV-2
R18	subject Arg1:T21 Arg2:T23	
T24	Concept 387 398	early stage
R19	in-context Arg1:T21 Arg2:T24	
T25	Concept 399 418	after symptom onset
R20	in-time Arg1:T21 Arg2:T25	
T26	Concept 528 532	CCoV
T27	Concept 533 543	strain A76
R21	is-a Arg1:T26 Arg2:T27	
T30	Concept 555 566	recombinant
T28	Concept 567 580	S 103 protein
R22	has-part Arg1:T26 Arg2:T28	
R23	has-property Arg1:T28 Arg2:T30	
T29	Concept 595 608	recombination
R24	causes Arg1:T29 Arg2:T28	
T31	Concept 617 627	serotype I
T32	Concept 632 639	II CCoV
T33	Concept 640 649	sequences
R25	target Arg1:T29 Arg2:T33	
R26	in-context Arg1:T32 Arg2:T33	
R27	in-context Arg1:T31 Arg2:T33	
T34	Concept 650 660	SARS-CoV-2
T35	Concept 678 685	segment
T36	Concept 667 677	disordered
R28	has-property Arg1:T35 Arg2:T36	
R29	has-part Arg1:T34 Arg2:T35	
T37	Concept 699 707	residues
R30	has-part Arg1:T35 Arg2:T37	
T38	Concept 691 698	168-289
R31	in-context Arg1:T37 Arg2:T38	
T39	Concept 714 724	Human SARS
T40	Concept 763 770	segment
R32	has-part Arg1:T39 Arg2:T40	
T41	Concept 750 762	unstructured
R33	has-property Arg1:T40 Arg2:T41	
T42	Concept 784 792	residues
R34	has-part Arg1:T40 Arg2:T42	
T43	Concept 776 783	145-289
R35	in-context Arg1:T43 Arg2:T42	
T44	Concept 818 827	direction
T45	Concept 808 817	evolution
R36	is-a Arg1:T44 Arg2:T45	
T46	Action 832 839	promote
A2	Uncertain T46
T47	Concept 844 854	appearance
R37	target Arg1:T46 Arg2:T47	
T48	Concept 863 870	subtype
R38	target Arg1:T47 Arg2:T48	
T49	Concept 874 882	COVID-19
R39	has-part Arg1:T48 Arg2:T49	
T50	Concept 858 862	mild
R40	has-property Arg1:T48 Arg2:T50	
T51	Concept 798 807	potential
R41	has-property Arg1:T44 Arg2:T51	
